Related Experiment Video
Updated: May 16, 2026
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
Published on: June 7, 2019
Studies of NVP-BEZ235 in melanoma
Joshua A Sznol1, Lucia B Jilaveanu, Harriet M Kluger
1Section of Medical Oncology, 333 Cedar Street, New Haven, Connecticut, 06520, USA.
Abstract:
The PI3k pathway represents an attractive target for drug development in melanoma, as numerous studies have shown that this pathway is active in malignant melanocytes. In addition, previous work has shown that multi-level targeting of this pathway might be more effective than targeting the pathway at a single level. In this review, we discuss targeting different members of this pathway, potential escape mechanisms, classes of specific molecular inhibitors, and development of NVP-BEZ235, a novel dual PI3k/mTOR inhibitor.
Insights
Targeting the PI3K pathway in melanoma is promising for drug development. Multi-level inhibition, including dual PI3K/mTOR inhibitors like NVP-BEZ235, may overcome resistance mechanisms.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The phosphoinositide 3-kinase (PI3K) pathway is frequently activated in melanoma.
- Targeting this pathway is a key strategy for melanoma drug development.
- Multi-level inhibition may offer superior efficacy compared to single-level targeting.
Purpose of the Study:
- To review strategies for targeting the PI3K pathway in melanoma.
- To discuss potential resistance mechanisms and molecular inhibitors.
- To highlight the development of NVP-BEZ235, a dual PI3K/mTOR inhibitor.
Main Methods:
- Literature review of PI3K pathway signaling in melanoma.
- Analysis of different targeting strategies and their effectiveness.
- Discussion of novel inhibitors and their preclinical development.
Main Results:
- The PI3K pathway is a validated target in melanoma.
- Various molecular inhibitors targeting different PI3K pathway components exist.
- NVP-BEZ235 demonstrates potential as a dual PI3K/mTOR inhibitor.
Conclusions:
- Targeting the PI3K pathway, particularly with multi-level inhibitors, holds significant therapeutic potential for melanoma.
- Understanding escape mechanisms is crucial for effective drug design.
- NVP-BEZ235 represents a promising novel therapeutic candidate for melanoma treatment.
